Back

Impact of advanced chronic kidney disease on treatment of heart failure patients. Insights from the Spanish Society of Cardiology-Excellence Heart Failure registry.

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - epidemiology, prognosis, outcome 10 Epidemiology, Prognosis, Outcome HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Alejandro Recio Mayoral

University Hospital of Virgen Macarena, Seville (Spain)

5 More presentations in this session

Presentation thumbnail
Prevalence of frailty according to different domains in chronic heart failure
Doctor D. Fernandez-Berges (Villanueva de la Serena, ES)
Abstract Slides Video
Presentation thumbnail
O2 consumption overshoot in patients with heart failure: crossing the line.
Doctor R. Carvalho (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Lipid risk profile in elderly patients with AHF and long-term follow-up
Doctor M. Garcia Melero (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Hyponatremia is highly prevalent and associated with worse clinical outcomes in HF population in Turkiye: results from TRends-HF
Associate Professor S. Murat (Eskisehir, TR)
Abstract Slides Video
Presentation thumbnail
Feasibility of using the ICHOM heart failure outcomes measurement set in real life in Spanish public hospitals. HF-Outcomes-Spain study.
Professor M. Crespo-Leiro (A Coruna, ES) Doctor D. Couto-Mallon (A Coruna, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - epidemiology, prognosis, outcome 10

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Differences in the optimization of pharmacological treatment in patients with heart failure and reduced ejection fraction and advanced chronic kidney disease.
thumbnail
Congress Presentation
Congestion as a crucial factor determining albuminuria in in patients with cardiorenal disease
thumbnail
Congress Presentation
Differences in the optimization of pharmacological treatment in patients with heart failure and reduced ejection fraction and advanced chronic kidney disease.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources